Bank of New York Mellon Corp decreased its holdings in Zoetis Inc. (NYSE: ZTS) by 24.3% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Cullen Frost Bankers Inc. reduced its stake in Zoetis Inc. (NYSE: ZTS) by 21.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The i

Zoetis: Undervalued And Oversold

08:00am, Saturday, 24'th Jan 2026
Zoetis, the global animal health leader, is deeply undervalued at a 19x forward P/E versus its 10-year average of 31.8x. ZTS is positioned to benefit from the secular trend of pet humanization, with 6
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 Healthcare Stocks Poised for a Comeback in 2026

01:05pm, Thursday, 22'nd Jan 2026
Don't wait too long to press the buy button on these comeback stories.
Trading at a once-in-a-decade low valuation, this leading animal healthcare stock deserves a long look from investors.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Dynasty Wealth Management LLC decreased its stake in Zoetis Inc. (NYSE: ZTS) by 82.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The
Guru Stock PicksChuck Royce has made the following transactions:Reduce in APYX by 1.27%Add in EBF by 4.13%New position in ANDGSmead Value Fund has made the foll
Davis Rea LTD. increased its holdings in Zoetis Inc. (NYSE: ZTS) by 10.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The instituti
I rate Zoetis (ZTS) a buy, citing a robust pipeline, upcoming product launches, and discounted valuation versus peers. ZTS targets new therapeutic white spaces—oncology, cardiology, and renal diseas
Ashton Thomas Securities LLC raised its position in Zoetis Inc. (NYSE: ZTS) by 760.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 12,76
Zoetis (ZTS) reached $125.32 at the closing of the latest trading day, reflecting a -1.45% change compared to its last close.
Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE